Alphagan P is owned by Allergan.
Alphagan P contains Brimonidine Tartrate.
Alphagan P has a total of 8 drug patents out of which 6 drug patents have expired.
Expired drug patents of Alphagan P are:
Alphagan P was authorised for market use on 16 March, 2001.
Alphagan P is available in solution/drops;ophthalmic dosage forms.
The generics of Alphagan P are possible to be released after 02 March, 2024.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9295641
(Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(1 year, 17 days ago) | |
US6562873
(Pediatric) | ALLERGAN | Compositions containing therapeutically active components having enhanced solubility |
Jan, 2022
(1 year, 17 days ago) | |
US9687443
(Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(1 year, 17 days ago) | |
US6627210
(Pediatric) | ALLERGAN | Compositions containing α-2-adrenergic agonist components |
Jan, 2022
(1 year, 9 days ago) | |
US6673337
(Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(1 year, 1 day ago) | |
US6641834
(Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(11 months ago) | |
US8858961 | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Sep, 2023
(7 months from now) | |
US8858961
(Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Mar, 2024
(1 year, 1 month from now) |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 16 March, 2001
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic